



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

## NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE

**Paris, January 19, 2015 – NEOVACS (Alternext Paris: ALNEV)**, a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that the Company will be presenting at the BIO CEO & Investor Conference to be held in New York on February 9-10, 2015.

The 17<sup>th</sup> Annual BIO CEO & Investor Conference attracts over 750 investors and takes place at the Waldorf Astoria, New York. A select number of biotech CEOs are given the opportunity to introduce their companies, technology and development programs.

Miguel Sieler, CEO of Neovacs, will present on February 10, 2015 at 9:30 am E.T.

### **About Neovacs**

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN $\alpha$ -Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

**For more information on Neovacs, visit [www.neovacs.fr](http://www.neovacs.fr)**

### **Contacts**

#### **NEOVACS**

Nathalie Trépo  
+33 (0)1 53 10 93 00  
[ntrepo@neovacs.com](mailto:ntrepo@neovacs.com)

#### **Press – Financial Communications- Publicis**

Stéphanie Tabouis  
+33 (0) 1 44 82 46 35  
[stephanie.tabouis@consultants.publicis.fr](mailto:stephanie.tabouis@consultants.publicis.fr)

#### **Investor Relations – Financial Communications Germany – MC Services**

Raimund Gabriel  
+49-89-210228-30  
[Raimund.Gabriel@mc-services.eu](mailto:Raimund.Gabriel@mc-services.eu)

**Press – U.S. Inquiries – The Ruth Group**

Melanie Sollid-Penton

1.646.536.7023

[msollid@theruthgroup.com](mailto:msollid@theruthgroup.com)